Tissue regeneration: The crosstalk between mesenchymal stem cells and immune response

Cellular Immunology

Volumn 326, Issue , 2018, Pages 86-93

  Qi, Kai ^a   Li, Na ^a   Zhang, Zhenyu ^b   Melino, Gerry ^c  

^a Chinese Academy of Sciences   (China)

^b Qihe Center for Disease Control and Prevention   (China)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Immune responses; Mesenchymal stem cells

Indexed keywords

ADAPTIVE IMMUNITY; ARTICLE; B LYMPHOCYTE; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOREGULATION; INNATE IMMUNITY; MACROPHAGE; MAST CELL; MESENCHYMAL STEM CELL; NATURAL KILLER CELL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TISSUE REGENERATION; CELL COMMUNICATION; CYTOLOGY; IMMUNE SYSTEM; IMMUNOLOGY; MESENCHYMAL STEM CELL TRANSPLANTATION; REGENERATION; WOUND HEALING;

ADAPTIVE IMMUNITY; CELL COMMUNICATION; HUMANS; IMMUNE SYSTEM; IMMUNITY, INNATE; IMMUNOMODULATION; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; REGENERATION; WOUND HEALING;

EID: 85036662285     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2017.11.010     Document Type: Article

References (140)

1. Ratcliffe, E., Glen, K.E., Naing, M.W., Williams, D.J., Current status and perspectives on stem cell-based therapies undergoing clinical trials for regenerative medicine: case studies. Br. Med. Bullet. 108 (2013), 73–94.
2. Trounson, A., McDonald, C., Stem cell therapies in clinical trials: progress and challenges. Cell Stem Cell 17 (2015), 11–22.
3. Tsukamoto, A., Abbot, S.E., Kadyk, L.C., DeWitt, N.D., Schaffer, D.V., Wertheim, J.A., Whittlesey, K.J., Werner, M.J., Challenging regeneration to transform medicine. Stem Cells Transl. Med. 5 (2016), 1–7.
4. Laroni, A., Novi, G., Kerlero de Rosbo, N., Uccelli, A., Towards clinical application of mesenchymal stem cells for treatment of neurological diseases of the central nervous system. J. Neuroimm. Pharmacol. 8 (2013), 1062–1076.
5. Hackett, C., Knight, J., Mao-Draayer, Y., Transplantation of Fas-deficient or wild-type neural stem/progenitor cells (NPCs) is equally efficient in treating experimental autoimmune encephalomyelitis (EAE). Am. J. Transl. Res. 6 (2014), 119–128.
6. Laroni, A., Rosbo, N.K., Uccelli, A., Mesenchymal stem cells for the treatment of neurological diseases: immunoregulation beyond neuroprotection. Immunol. Lett. 168 (2015), 183–190.
7. Shi, Y., Hu, G., Su, J., Li, W., Chen, Q., Shou, P., Xu, C., Chen, X., Huang, Y., Zhu, Z., Huang, X., Han, X., Xie, N., Ren, G., Mesenchymal stem cells: a new strategy for immunosuppression and tissue repair. Cell Res. 20 (2010), 510–518.
8. Wang, Y., Chen, X., Cao, W., Shi, Y., Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. Nat. Immunol. 15 (2014), 1009–1016.
9. Ben-Ami, E., Berrih-Aknin, S., Miller, A., Mesenchymal stem cells as an immunomodulatory therapeutic strategy for autoimmune diseases. Autoimm. Rev. 10 (2011), 410–415.
10. Glenn, J.D., Whartenby, K.A., Mesenchymal stem cells: emerging mechanisms of immunomodulation and therapy. World J. Stem Cells 6 (2014), 526–539.
11. Pourgholaminejad, A., Aghdami, N., Baharvand, H., Moazzeni, S.M., The effect of pro-inflammatory cytokines on immunophenotype, differentiation capacity and immunomodulatory functions of human mesenchymal stem cells. Cytokine 85 (2016), 51–60.
12. Pittenger, M.F., Mackay, A.M., Beck, S.C., Jaiswal, R.K., Douglas, R., Mosca, J.D., Moorman, M.A., Simonetti, D.W., Craig, S., Marshak, D.R., Multilineage potential of adult human mesenchymal stem cells. Science 284 (1999), 143–147.
13. Bianco, P., “Mesenchymal” stem cells. Ann. Rev. Cell Dev. Biol. 30 (2014), 677–704.
14. Barry, F.P., Murphy, J.M., Mesenchymal stem cells: clinical applications and biological characterization. Int. J. Biochem. Cell Biol. 36 (2004), 568–584.
15. Lin, C.S., Xin, Z.C., Dai, J., Lue, T.F., Commonly used mesenchymal stem cell markers and tracking labels: limitations and challenges. Histol. Histopathol. 28 (2013), 1109–1116.
16. Mendez-Ferrer, S., Michurina, T.V., Ferraro, F., Mazloom, A.R., Macarthur, B.D., Lira, S.A., Scadden, D.T., Ma'ayan, A., Enikolopov, G.N., Frenette, P.S., Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 466 (2010), 829–834.
17. Roberts, E.W., Deonarine, A., Jones, J.O., Denton, A.E., Feig, C., Lyons, S.K., Espeli, M., Kraman, M., McKenna, B., Wells, R.J., Zhao, Q., Caballero, O.L., Larder, R., Coll, A.P., O'Rahilly, S., Brindle, K.M., Teichmann, S.A., Tuveson, D.A., Fearon, D.T., Depletion of stromal cells expressing fibroblast activation protein-alpha from skeletal muscle and bone marrow results in cachexia and anemia. J. Exp. Med. 210 (2013), 1137–1151.
18. Zhao, H., Feng, J., Seidel, K., Shi, S., Klein, O., Sharpe, P., Chai, Y., Secretion of shh by a neurovascular bundle niche supports mesenchymal stem cell homeostasis in the adult mouse incisor. Cell Stem Cell 14 (2014), 160–173.
19. Zhou, B.O., Yue, R., Murphy, M.M., Peyer, J.G., Morrison, S.J., Leptin-receptor-expressing mesenchymal stromal cells represent the main source of bone formed by adult bone marrow. Cell Stem Cell 15 (2014), 154–168.
20. J.D.M. Kevin, R. Mcintosh, Elena N. Klyushnenkova, Mesenchymal stem cells for prevention and treatment of immune responses in transplantation USWO1999047163 A2, 1998.
21. Luu, N.T., McGettrick, H.M., Buckley, C.D., Newsome, P.N., Rainger, G.E., Frampton, J., Nash, G.B., Crosstalk between mesenchymal stem cells and endothelial cells leads to downregulation of cytokine-induced leukocyte recruitment. Stem Cells 31 (2013), 2690–2702.
22. Le Blanc, K., Mougiakakos, D., Multipotent mesenchymal stromal cells and the innate immune system. Nat. Rev. Immunol. 12 (2012), 383–396.
23. Ren, G., Zhao, X., Wang, Y., Zhang, X., Chen, X., Xu, C., Yuan, Z.R., Roberts, A.I., Zhang, L., Zheng, B., Wen, T., Han, Y., Rabson, A.B., Tischfield, J.A., Shao, C., Shi, Y., CCR2-dependent recruitment of macrophages by tumor-educated mesenchymal stromal cells promotes tumor development and is mimicked by TNFalpha. Cell Stem Cell 11 (2012), 812–824.
24. Cho, K.A., Lee, J.K., Kim, Y.H., Park, M., Woo, S.Y., Ryu, K.H., Mesenchymal stem cells ameliorate B-cell-mediated immune responses and increase IL-10-expressing regulatory B cells in an EBI3-dependent manner. Cell. Mol. Immunol., 2017.
25. Wang, D., Li, S.P., Fu, J.S., Bai, L., Guo, L., Resveratrol augments therapeutic efficiency of mouse bone marrow mesenchymal stem cell-based therapy in experimental autoimmune encephalomyelitis. Int. J. Dev. Neurosci. 49 (2016), 60–66.
26. Contreras, R.A., Figueroa, F.E., Djouad, F., Luz-Crawford, P., Mesenchymal stem cells regulate the innate and adaptive immune responses dampening arthritis progression. Stem Cells Int., 2016, 2016, 3162743.
27. Tyndall, A., van Laar, J.M., Stem cell transplantation and mesenchymal cells to treat autoimmune diseases. Presse Medicale (Paris, France: 1983) 45 (2016), e159–e169.
28. Alviano, F., Lanzoni, G., Moretti, S., Cuneo, A., A functional role for soluble HLA-G antigens in immune modulation mediated by mesenchymal stromal cells. Cytotherapy 10 (2008), 364–375.
29. Nasef, A., Mazurier, C., Bouchet, S., Franã§Ois, S., Chapel, A., Thierry, D., Gorin, N.C., Fouillard, L., Leukemia inhibitory factor: role in human mesenchymal stem cells mediated immunosuppression. Cell. Immunol. 253 (2008), 16–22.
30. Choi, H., Lee, R.H., Bazhanov, N., Oh, J.Y., Prockop, D.J., Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing TLR2/NF-κB signaling in resident macrophages. Blood 118 (2011), 330–338.
31. Wang, N., Li, Q., Zhang, L., Lin, H., Hu, J., Li, D., Shi, S., Cui, S., Zhou, J., Ji, J., Mesenchymal stem cells attenuate peritoneal injury through secretion of TSG-6. PLoS One, 7, 2012, e43768.
32. Chabannes, D., Hill, M., Merieau, E., Rossignol, J., Brion, R., Soulillou, J.P., Anegon, I., Cuturi, M.C., A role for heme oxygenase-1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells. Blood 110 (2007), 3691–3694.
33. Mougiakakos, D., Jitschin, R., Johansson, C.C., Okita, R., Kiessling, R., Le, B.K., The impact of inflammatory licensing on heme oxygenase-1-mediated induction of regulatory T cells by human mesenchymal stem cells. Blood 117 (2011), 4826–4835.
34. Djouad, F., Charbonnier, L.M., Bouffi, C., Louisplence, P., Bony, C., Apparailly, F., Cantos, C., Jorgensen, C., Noël, D., Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells 25 (2007), 2025–2032.
35. Najar, M., Rouas, R., Raicevic, G., Boufker, H.I., Lewalle, P., Meuleman, N., Bron, D., Toungouz, M., Martiat, P., Lagneaux, L., Mesenchymal stromal cells promote or suppress the proliferation of T lymphocytes from cord blood and peripheral blood: the importance of low cell ratio and role of interleukin-6. Cytotherapy 11 (2009), 570–583.
36. Patel, S.A., Meyer, J.R., Greco, S.J., Corcoran, K.E., Bryan, M., Rameshwar, P., Mesenchymal stem cells protect breast cancer cells through regulatory T cells: role of mesenchymal stem cell-derived TGF-beta. J. Immunol., 184, 2010, 5885.
37. Sotiropoulou, P.A., Perez, S.A., Gritzapis, A.D., Baxevanis, C.N., Michael, P.P.D., Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 24 (2006), 74–85.
38. English, K., Ryan, J., Murphy, L.M., Barry, F., Mahon, B., Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells. Clin. Exp. Immunol. 156 (2009), 149–160.
39. Ylöstalo, J.H., Bartosh, T.J., Coble, K., Prockop, D.J., Human mesenchymal stem/stromal cells cultured as spheroids are self-activated to produce prostaglandin E2 that directs stimulated macrophages into an anti-inflammatory phenotype. Stem Cells 30 (2012), 2283–2296.
40. Spaggiari, G.M., Abdelrazik, H., Becchetti, F., Moretta, L., MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood, 113, 2009, 6576.
41. Luz-Crawford, P., Djouad, F., Toupet, K., Bony, C., Franquesa, M., Hoogduijn, M.J., Jorgensen, C., Noel, D., Mesenchymal stem cell-derived interleukin 1 receptor antagonist promotes macrophage polarization and inhibits B cell differentiation. Stem Cells (Dayton, Ohio) 34 (2016), 483–492.
42. Li, M., Sun, X., Kuang, X., Liao, Y., Li, H., Luo, D., Mesenchymal stem cells suppress CD8+ T cell-mediated activation by suppressing natural killer group 2, member D protein receptor expression and secretion of prostaglandin E2, indoleamine 2, 3-dioxygenase and transforming growth factor-beta. Clin. Exp. Immunol. 178 (2014), 516–524.
43. Benvenuto, F., Ferrari, S., Gerdoni, E., Gualandi, F., Frassoni, F., Pistoia, V., Mancardi, G., Uccelli, A., Human mesenchymal stem cells promote survival of T cells in a quiescent state. Stem Cells 25 (2007), 1753–1760.
44. Ghannam, S., Pene, J., Moquet-Torcy, G., Jorgensen, C., Yssel, H., Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J. Immunol. 185 (2010), 302–312.
45. Obermajer, N., Popp, F.C., Soeder, Y., Haarer, J., Geissler, E.K., Schlitt, H.J., Dahlke, M.H., Conversion of Th17 into IL-17A(neg) regulatory T cells: a novel mechanism in prolonged allograft survival promoted by mesenchymal stem cell-supported minimized immunosuppressive therapy. J. Immunol. 193 (2014), 4988–4999.
46. Duffy, M.M., Pindjakova, J., Hanley, S.A., McCarthy, C., Weidhofer, G.A., Sweeney, E.M., English, K., Shaw, G., Murphy, J.M., Barry, F.P., Mahon, B.P., Belton, O., Ceredig, R., Griffin, M.D., Mesenchymal stem cell inhibition of T-helper 17 cell-differentiation is triggered by cell-cell contact and mediated by prostaglandin E2 via the EP4 receptor. Eur. J. Immunol. 41 (2011), 2840–2851.
47. Favaro, E., Carpanetto, A., Lamorte, S., Fusco, A., Caorsi, C., Deregibus, M.C., Bruno, S., Amoroso, A., Giovarelli, M., Porta, M., Perin, P.C., Tetta, C., Camussi, G., Zanone, M.M., Human mesenchymal stem cell-derived microvesicles modulate T cell response to islet antigen glutamic acid decarboxylase in patients with type 1 diabetes. Diabetologia 57 (2014), 1664–1673.
48. Ren, G., Zhao, X., Inflammatory cytokine-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression. J. Immunol., 184, 2010, 2321.
49. Sheng, H., Wang, Y., Jin, Y., Zhang, Q., Zhang, Y., Wang, L., Shen, B., Yin, S., Liu, W., Cui, L., A critical role of IFNgamma in priming MSC-mediated suppression of T cell proliferation through up-regulation of B7–H1. Cell Res., 18, 2008, 846.
50. Beyth, S., Borovsky, Z., Mevorach, D., Liebergall, M., Gazit, Z., Aslan, H., Galun, E., Rachmilewitz, J., Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood, 105, 2005, 2214.
51. Di Nicola, M., Carlo-Stella, C., Magni, M., Milanesi, M., Longoni, P.D., Matteucci, P., Grisanti, S., Gianni, A.M., Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99 (2002), 3838–3843.
52. Tse, W.T., Pendleton, J.D., Beyer, W.M., Egalka, M.C., Guinan, E.C., Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 75 (2003), 389–397.
53. Aggarwal, S., Pittenger, M.F., Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105 (2005), 1815–1822.
54. Darlington, P.J., Boivin, M.N., Renoux, C., Francois, M., Galipeau, J., Freedman, M.S., Atkins, H.L., Cohen, J.A., Solchaga, L., Bar-Or, A., Reciprocal Th1 and Th17 regulation by mesenchymal stem cells: implication for multiple sclerosis. Ann. Neurol. 68 (2010), 540–545.
55. Mohammadzadeh, A., Pourfathollah, A.A., Shahrokhi, S., Hashemi, S.M., Moradi, S.L., Soleimani, M., Immunomodulatory effects of adipose-derived mesenchymal stem cells on the gene expression of major transcription factors of T cell subsets. Int. Immunopharmacol. 20 (2014), 316–321.
56. Angoulvant, D., Clerc, A., Benchalal, S., Galambrun, C., Farre, A., Bertrand, Y., Eljaafari, A., Human mesenchymal stem cells suppress induction of cytotoxic response to alloantigens. Biorheology 41 (2004), 469–476.
57. Ren, G., Zhang, L., Zhao, X., Xu, G., Zhang, Y., Roberts, A.I., Zhao, R.C., Shi, Y., Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell, 2, 2008, 141.
58. Krampera, M., Cosmi, L., Angeli, R., Pasini, A., Liotta, F., Andreini, A., Santarlasci, V., Mazzinghi, B., Pizzolo, G., Vinante, F., Romagnani, P., Maggi, E., Romagnani, S., Annunziato, F., Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells (Dayton, Ohio) 24 (2006), 386–398.
59. Ren, G., Su, J., Zhang, L., Zhao, X., Ling, W., L'Huillie, A., Zhang, J., Lu, Y., Roberts, A.I., Ji, W., Zhang, H., Rabson, A.B., Shi, Y., Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells 27 (2009), 1954–1962.
60. Su, J., Chen, X., Huang, Y., Li, W., Li, J., Cao, K., Cao, G., Zhang, L., Li, F., Roberts, A.I., Kang, H., Yu, P., Ren, G., Ji, W., Wang, Y., Shi, Y., Phylogenetic distinction of iNOS and IDO function in mesenchymal stem cell-mediated immunosuppression in mammalian species. Cell Death Different. 21 (2014), 388–396.
61. Li, W., Ren, G., Huang, Y., Su, J., Han, Y., Li, J., Chen, X., Cao, K., Chen, Q., Shou, P., Zhang, L., Yuan, Z.R., Roberts, A.I., Shi, S., Le, A.D., Shi, Y., Mesenchymal stem cells: a double-edged sword in regulating immune responses. Cell Death Different. 19 (2012), 1505–1513.
62. Stagg, J., Galipeau, J., Mechanisms of immune modulation by mesenchymal stromal cells and clinical translation. Curr. Mol. Med. 13 (2013), 856–867.
63. Duffy, M.M., Pindjakova, J., Hanley, S.A., Mccarthy, C., Weidhofer, G.A., Sweeney, E.M., English, K., Shaw, G., Murphy, J.M., Barry, F.P., Mesenchymal stem cell inhibition of T-helper 17 cell-differentiation is triggered by cell–cell contact and mediated by prostaglandin E2 via the EP4 receptor. Eur. J. Immunol., 41, 2011, 2840.
64. Luzcrawford, P., Noël, D., Fernandez, X., Khoury, M., Figueroa, F., Carrión, F., Jorgensen, C., Djouad, F., Mesenchymal stem cells repress Th17 molecular program through the PD-1 pathway. PLoS One, 7, 2012, e45272.
65. Rafei, M., Campeau, P.M., Aguilarmahecha, A., Buchanan, M., Williams, P., Birman, E., Yuan, S., Young, Y.K., Boivin, M.N., Forner, K., Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner. J. Immunol. 182 (2009), 5994–6002.
66. Darlington, P.J., Boivin, M.N., PhD, C.R.M., Bsc, M.F., Jacques Galipeau, M.D., Freedman, M.S., Atkins, H.L., Cohen, J.A., Solchaga, L., Amit-Bar-Or, M.D., Reciprocal Th1 and Th17 regulation by mesenchymal stem cells: Implication for multiple sclerosis. Ann. Neurol., 68, 2010, 540.
67. Bai, L., Lennon, D.P., Eaton, V., Maier, K., Caplan, A.I., Miller, S.D., Miller, R.H., Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia 57 (2010), 1192–1203.
68. Bernardo, M.E., Fibbe, W.E., Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell 13 (2013), 392–402.
69. Chaudhry, A., Rudensky, A.Y., Control of inflammation by integration of environmental cues by regulatory T cells. J. Clin. Invest. 123 (2013), 939–944.
70. Burr, S.P., Dazzi, F., Garden, O.A., Mesenchymal stromal cells and regulatory T cells: the Yin and Yang of peripheral tolerance?. Immunol. Cell Biol. 91 (2013), 12–18.
71. Prevosto, C., Zancolli, M., Canevali, P., Zocchi, M.R., Poggi, A., Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. Haematologica 92 (2007), 881–888.
72. English, K., Ryan, J.M., Tobin, L., Murphy, M.J., Barry, F.P., Mahon, B.P., Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells. Clin. Exp. Immunol. 156 (2009), 149–160.
73. Melief, S.M., Schrama, E., Brugman, M.H., Tiemessen, M.M., Hoogduijn, M.J., Fibbe, W.E., Roelofs, H., Multipotent stromal cells induce human regulatory T cells through a novel pathway involving skewing of monocytes toward anti-inflammatory macrophages. Stem Cells 31 (2013), 1980–1991.
74. Maccario, R., Podesta, M., Moretta, A., Cometa, A., Comoli, P., Montagna, D., Daudt, L., Ibatici, A., Piaggio, G., Pozzi, S., Frassoni, F., Locatelli, F., Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica 90 (2005), 516–525.
75. Selmani, Z., Naji, A., Zidi, I., Favier, B., Gaiffe, E., Obert, L., Borg, C., Saas, P., Tiberghien, P., Rouas-Freiss, N., Carosella, E.D., Deschaseaux, F., Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells 26 (2008), 212–222.
76. Ge, W., Jiang, J., Baroja, M.L., Arp, J., Zassoko, R., Liu, W., Bartholomew, A., Garcia, B., Wang, H., Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance. Am. J. Transplant. 9 (2009), 1760–1772.
77. Kim, Y.H., Wee, Y.M., Choi, M.Y., Lim, D.G., Kim, S.C., Han, D.J., Interleukin (IL)-10 induced by CD11b(+) cells and IL-10-activated regulatory T cells play a role in immune modulation of mesenchymal stem cells in rat islet allografts. Mol. Med. 17 (2011), 697–708.
78. Ge, W., Jiang, J., Arp, J., Liu, W., Garcia, B., Wang, H., Regulatory T-cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2,3-dioxygenase expression. Transplantation 90 (2010), 1312–1320.
79. Corcione, A., Benvenuto, F., Ferretti, E., Giunti, D., Cappiello, V., Cazzanti, F., Risso, M., Gualandi, F., Mancardi, G.L., Pistoia, V., Uccelli, A., Human mesenchymal stem cells modulate B-cell functions. Blood 107 (2006), 367–372.
80. Spaggiari, G.M., Capobianco, A., Becchetti, S., Mingari, M.C., Moretta, L., Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 107 (2006), 1484–1490.
81. Augello, A., Tasso, R., Negrini, S.M., Amateis, A., Indiveri, F., Cancedda, R., Pennesi, G., Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur. J. Immunol. 35 (2005), 1482–1490.
82. Asari, S., Itakura, S., Ferreri, K., Liu, C.P., Kuroda, Y., Kandeel, F., Mullen, Y., Mesenchymal stem cells suppress B-cell terminal differentiation. Exp. Hematol. 37 (2009), 604–615.
83. Che, N., Li, X., Zhou, S., Liu, R., Shi, D., Lu, L., Sun, L., Umbilical cord mesenchymal stem cells suppress B-cell proliferation and differentiation. Cell. Immunol. 274 (2012), 46–53.
84. Rasmusson, I., Le Blanc, K., Sundberg, B., Ringden, O., Mesenchymal stem cells stimulate antibody secretion in human B cells. Scand. J. Immunol. 65 (2007), 336–343.
85. Poggi, A., Prevosto, C., Massaro, A.M., Negrini, S., Urbani, S., Pierri, I., Saccardi, R., Gobbi, M., Zocchi, M.R., Interaction between human NK cells and bone marrow stromal cells induces NK cell triggering: role of NKp30 and NKG2D receptors. J. Immunol. 175 (2005), 6352–6360.
86. Sotiropoulou, P.A., Perez, S.A., Gritzapis, A.D., Baxevanis, C.N., Papamichail, M., Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 24 (2006), 74–85.
87. Noone, C., Kihm, A., English, K., O'Dea, S., Mahon, B.P., IFN-gamma stimulated human umbilical-tissue-derived cells potently suppress NK activation and resist NK-mediated cytotoxicity in vitro. Stem Cells Dev. 22 (2013), 3003–3014.
88. Pende, D., Parolini, S., Pessino, A., Sivori, S., Augugliaro, R., Morelli, L., Marcenaro, E., Accame, L., Malaspina, A., Biassoni, R., Identification and molecular characterization of Nkp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J. Exp. Med. 190 (1999), 1505–1516.
89. DeSantis, C., Siegel, R., Bandi, P., Jemal, A., Breast cancer statistics, 2011. CA 61 (2011), 409–418.
90. Moretta, L., Moretta, A., Unravelling natural killer cell function: triggering and inhibitory human NK receptors. Embo J. 23 (2004), 255–259.
91. Wu, J., Song, Y., Bakker, A.B., Bauer, S., Spies, T., Lanier, L.L., Phillips, J.H., An activating immunoreceptor complex formed by NKG2D and DAP10. Science, 285, 1999, 730.
92. Shibuya, A., Campbell, D., Hannum, C., Yssel, H., Franz-Bacon, K., Mcclanahan, T., Kitamura, T., Nicholl, J., Sutherland, G.R., Lanier, L.L., DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity, 4, 1996, 573.
93. Dubois, B., Bridon, J.M., Fayette, J., Barthelemy, C., Banchereau, J., Caux, C., Briere, F., Dendritic cells directly modulate B cell growth and differentiation. J. Leukocyte Biol. 66 (1999), 224–230.
94. Gerosa, F., Baldani-Guerra, B., Nisii, C., Marchesini, V., Carra, G., Trinchieri, G., Reciprocal activating interaction between natural killer cells and dendritic cells. J. Exp. Med. 195 (2002), 327–333.
95. Deng, Y., Yi, S., Wang, G., Cheng, J., Zhang, Y., Chen, W., Tai, Y., Chen, S., Chen, G., Liu, W., Zhang, Q., Yang, Y., Umbilical cord-derived mesenchymal stem cells instruct dendritic cells to acquire tolerogenic phenotypes through the IL-6-mediated upregulation of SOCS1. Stem Cells Dev. 23 (2014), 2080–2092.
96. Zhang, B., Liu, R., Shi, D., Liu, X., Chen, Y., Dou, X., Zhu, X., Lu, C., Liang, W., Liao, L., Zenke, M., Zhao, R.C., Mesenchymal stem cells induce mature dendritic cells into a novel Jagged-2-dependent regulatory dendritic cell population. Blood 113 (2009), 46–57.
97. Su, W.R., Zhang, Q.Z., Shi, S.H., Nguyen, A.L., Le, A.D., Human gingiva-derived mesenchymal stromal cells attenuate contact hypersensitivity via prostaglandin E2-dependent mechanisms. Stem Cells 29 (2011), 1849–1860.
98. Liu, Y., Yin, Z., Zhang, R., Yan, K., Chen, L., Chen, F., Huang, W., Lv, B., Sun, C., Jiang, X., MSCs inhibit bone marrow-derived DC maturation and function through the release of TSG-6. Biochem. Biophys. Res Commun. 450 (2014), 1409–1415.
99. Nauta, A.J., Kruisselbrink, A.B., Lurvink, E., Willemze, R., Fibbe, W.E., Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells. J. Immunol. 177 (2006), 2080–2087.
100. Du Rocher, B., Mencalha, A.L., Gomes, B.E., Abdelhay, E., Mesenchymal stromal cells impair the differentiation of CD14(++) CD16(-) CD64(+) classical monocytes into CD14(++) CD16(+) CD64(++) activate monocytes. Cytotherapy 14 (2012), 12–25.
101. Prockop, D.J., Concise review: two negative feedback loops place mesenchymal stem/stromal cells at the center of early regulators of inflammation. Stem Cells 31 (2013), 2042–2046.
102. Abumaree, M.H., Al Jumah, M.A., Kalionis, B., Jawdat, D., Al Khaldi, A., Abomaray, F.M., Fatani, A.S., Chamley, L.W., Knawy, B.A., Human placental mesenchymal stem cells (pMSCs) play a role as immune suppressive cells by shifting macrophage differentiation from inflammatory M1 to anti-inflammatory M2 macrophages. Stem Cell Rev. 9 (2013), 620–641.
103. Giunti, D., Parodi, B., Usai, C., Vergani, L., Casazza, S., Bruzzone, S., Mancardi, G., Uccelli, A., Mesenchymal stem cells shape microglia effector functions through the release of CX3CL1. Stem Cells 30 (2012), 2044–2053.
104. Oh, J.Y., Ko, J.H., Lee, H.J., Yu, J.M., Choi, H., Kim, M.K., Wee, W.R., Prockop, D.J., Mesenchymal stem/stromal cells inhibit the NLRP3 inflammasome by decreasing mitochondrial reactive oxygen species. Stem Cells 32 (2014), 1553–1563.
105. Choi, H., Lee, R.H., Bazhanov, N., Oh, J.Y., Prockop, D.J., Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing TLR2/NF-kappaB signaling in resident macrophages. Blood 118 (2011), 330–338.
106. Nemeth, K., Leelahavanichkul, A., Yuen, P.S., Mayer, B., Parmelee, A., Doi, K., Robey, P.G., Leelahavanichkul, K., Koller, B.H., Brown, J.M., Hu, X., Jelinek, I., Star, R.A., Mezey, E., Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat. Med. 15 (2009), 42–49.
107. Zanier, E.R., Pischiutta, F., Riganti, L., Marchesi, F., Turola, E., Fumagalli, S., Perego, C., Parotto, E., Vinci, P., Veglianese, P., D'Amico, G., Verderio, C., De Simoni, M.G., Bone marrow mesenchymal stromal cells drive protective M2 microglia polarization after brain trauma. Neurotherapeutics 11 (2014), 679–695.
108. Sun, H., Benardais, K., Stanslowsky, N., Thau-Habermann, N., Hensel, N., Huang, D., Claus, P., Dengler, R., Stangel, M., Petri, S., Therapeutic potential of mesenchymal stromal cells and MSC conditioned medium in Amyotrophic Lateral Sclerosis (ALS)–in vitro evidence from primary motor neuron cultures, NSC-34 cells, astrocytes and microglia. PLoS One, 8, 2013, e72926.
109. Francois, M., Romieu-Mourez, R., Li, M., Galipeau, J., Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation. Mol. Ther. 20 (2012), 187–195.
110. Nemeth, K., Wilson, T., Rada, B., Parmelee, A., Mayer, B., Buzas, E., Falus, A., Key, S., Masszi, T., Karpati, S., Mezey, E., Characterization and function of histamine receptors in human bone marrow stromal cells. Stem Cells 30 (2012), 222–231.
111. Brown, J.M., Nemeth, K., Kushnir-Sukhov, N.M., Metcalfe, D.D., Mezey, E., Bone marrow stromal cells inhibit mast cell function via a COX2-dependent mechanism. Clin. Exp. Allergy 41 (2011), 526–534.
112. Kim, H.S., Yun, J.W., Shin, T.H., Lee, S.H., Lee, B.C., Yu, K.R., Seo, Y., Lee, S., Kang, T.W., Choi, S.W., Seo, K.W., Kang, K.S., Human umbilical cord blood mesenchymal stem cell-derived PGE2 and TGF-beta1 alleviate atopic dermatitis by reducing mast cell degranulation. Stem Cells 33 (2015), 1254–1266.
113. Su, W., Wan, Q., Huang, J., Han, L., Chen, X., Chen, G., Olsen, N., Zheng, S.G., Liang, D., Culture medium from TNF-alpha-stimulated mesenchymal stem cells attenuates allergic conjunctivitis through multiple antiallergic mechanisms. J. Allergy Clin. Immunol. 136 (2015), 423–432 e428.
114. Wick, G., Grundtman, C., Mayerl, C., Wimpissinger, T.F., Feichtinger, J., Zelger, B., Sgonc, R., Wolfram, D., The immunology of fibrosis. Ann. Rev. Immunol. 31 (2013), 107–135.
115. Campard, D., Lysy, P.A., Najimi, M., Sokal, E.M., Native umbilical cord matrix stem cells express hepatic markers and differentiate into hepatocyte-like cells. Gastroenterology 134 (2008), 833–848.
116. Zappia, E., Casazza, S., Pedemonte, E., Benvenuto, F., Bonanni, I., Gerdoni, E., Giunti, D., Ceravolo, A., Cazzanti, F., Frassoni, F., Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 106 (2016), 1755–1761.
117. Szablewski, L., Role of immune system in type 1 diabetes mellitus pathogenesis. Int. Immunopharmacol. 22 (2014), 182–191.
118. Urbán, V.S., Kiss, J., Kovács, J., Gócza, E., Vas, V., Monostori, V., Ferenc, U.P.D., Mesenchymal stem cells cooperate with bone marrow cells in therapy of diabetes. Stem Cells 26 (2008), 244–253.
119. Papadopoulou, A., Yiangou, M., Athanasiou, E., Zogas, N., Kaloyannidis, P., Batsis, I., Fassas, A., Anagnostopoulos, A., Yannaki, E., Mesenchymal stem cells are conditionally therapeutic in preclinical models of rheumatoid arthritis. Ann. Rheumat. Dis., 71, 2012, 1733.
120. Liu, Y., Mu, R., Wang, S., Long, L., Liu, X., Li, R., Sun, J., Guo, J., Zhang, X., Guo, J., Therapeutic potential of human umbilical cord mesenchymal stem cells in the treatment of rheumatoid arthritis. Arthritis Res. Ther., 12, 2010, R210.
121. Ball, L.M., Egeler, R.M., Acute GvHD: pathogenesis and classification. Bone Marrow Transplant., 41(Suppl 2), 2008, S58.
122. Choi, J., Sang, T.K., Craft, J., The pathogenesis of systemic lupus erythematosus – an update. Curr. Opin. Immunol. 24 (2012), 651–657.
123. Liang, J., Sun, L., Mesenchymal stem cells transplantation for systemic lupus erythematosus. Int. J. Rheumat. Dis 18 (2015), 164–171.
124. Ma, X., Che, N., Gu, Z., Huang, J., Wang, D., Liang, J., Hou, Y., Gilkeson, G., Lu, L., Sun, L., Allogenic mesenchymal stem cell transplantation ameliorates nephritis in lupus mice via inhibition of B-cell activation. Cell Transplant., 22, 2013, 2279.
125. Le Blanc, K., Rasmusson, I., Sundberg, B., Gotherstrom, C., Hassan, M., Uzunel, M., Ringden, O., Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363 (2004), 1439–1441.
126. Le Blanc, K., Frassoni, F., Ball, L., Locatelli, F., Roelofs, H., Lewis, I., Lanino, E., Sundberg, B., Bernardo, M.E., Remberger, M., Dini, G., Egeler, R.M., Bacigalupo, A., Fibbe, W., Ringden, O., Developmental, B., Committee of the European Group for, T. Marrow, mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371 (2008), 1579–1586.
127. Ball, L.M., Bernardo, M.E., Roelofs, H., van Tol, M.J., Contoli, B., Zwaginga, J.J., Avanzini, M.A., Conforti, A., Bertaina, A., Giorgiani, G., Jol-van der Zijde, C.M., Zecca, M., Le Blanc, K., Frassoni, F., Egeler, R.M., Fibbe, W.E., Lankester, A.C., Locatelli, F., Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease. Br. J. Haematol. 163 (2013), 501–509.
128. Dander, E., Lucchini, G., Vinci, P., Introna, M., Masciocchi, F., Perseghin, P., Balduzzi, A., Bonanomi, S., Longoni, D., Gaipa, G., Belotti, D., Parma, M., Algarotti, A., Capelli, C., Golay, J., Rovelli, A., Rambaldi, A., Biondi, A., Biagi, E., D'Amico, G., Mesenchymal stromal cells for the treatment of graft-versus-host disease: understanding the in vivo biological effect through patient immune monitoring. Leukemia 26 (2012), 1681–1684.
129. Krampera, M., Mesenchymal stromal cell ‘licensing’: a multistep process. Leukemia 25 (2011), 1408–1414.
130. Polchert, D., Sobinsky, J., Douglas, G., Kidd, M., Moadsiri, A., Reina, E., Genrich, K., Mehrotra, S., Setty, S., Smith, B., Bartholomew, A., IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur. J. Immunol. 38 (2008), 1745–1755.
131. Duijvestein, M., Wildenberg, M.E., Welling, M.M., Hennink, S., Molendijk, I., van Zuylen, V.L., Bosse, T., Vos, A.C., de Jonge-Muller, E.S., Roelofs, H., van der Weerd, L., Verspaget, H.W., Fibbe, W.E., te Velde, A.A., van den Brink, G.R., Hommes, D.W., Pretreatment with interferon-gamma enhances the therapeutic activity of mesenchymal stromal cells in animal models of colitis. Stem Cells 29 (2011), 1549–1558.
132. Sudres, M., Norol, F., Trenado, A., Grégoire, S., Charlotte, F., Levacher, B., Lataillade, J.J., Bourin, P., Holy, X., Vernant, J.P., Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice. J. Immunol., 176, 2006, 7761.
133. Inoue, S., Popp, F.C., Koehl, G.E., Piso, P., Schlitt, H.J., Geissler, E.K., Dahlke, M.H., Immunomodulatory effects of mesenchymal stem cells in a rat organ transplant model. Transplantation, 81, 2006, 1589.
134. Ireland, S.J., Monson, N.L., Davis, L.S., Seeking balance: potentiation and inhibition of multiple sclerosis autoimmune responses by IL-6 and IL-10. Cytokine, 73, 2015, 236.
135. Travis, M.A., Sheppard, D., TGF-β activation and function in immunity. Ann. Rev. Immunol., 32, 2014, 51.
136. Enayat, N., Bellemore, S.M., Bhagirath, S., IL-22, cell regeneration and autoimmunity. Cytokine 74 (2015), 35–42.
137. Renner, P., Eggenhofer, E., Rosenauer, A., Popp, F.C., Steinmann, J.F., Slowik, P., Geissler, E.K., Piso, P., Schlitt, H.J., Dahlke, M.H., Mesenchymal stem cells require a sufficient, ongoing immune response to exert their immunosuppressive function. Transplant. Proceed., 41, 2009, 2607.
138. Li, W., Ren, G., Huang, Y., Su, J., Han, Y., Li, J., Chen, X., Cao, K., Chen, Q., Shou, P., Mesenchymal stem cells: a double-edged sword in regulating immune responses. Cell Death Different. 19 (2012), 1505–1513.
139. Cao, W., Cao, K., Cao, J., Wang, Y., Shi, Y., Mesenchymal stem cells and adaptive immune responses. Immunol. Lett. 168 (2015), 147–153.
140. Te Boome, L.C., Mansilla, C., van der Wagen, L.E., Lindemans, C.A., Petersen, E.J., Spierings, E., Thus, K.A., Westinga, K., Plantinga, M., Bierings, M., Broers, A.E., Cuijpers, M.L., van Imhoff, G.W., Janssen, J.J., Huisman, C., Zeerleder, S., Huls, G., Boelens, J.J., Wulffraat, N.M., Slaper-Cortenbach, I.C., Kuball, J., Biomarker profiling of steroid-resistant acute GVHD in patients after infusion of mesenchymal stromal cells. Leukemia 29 (2015), 1839–1846.